Lanzisera Rosaria, Gervasoni Fabrizio, Rossato Maria Sole, Tarantino Germano, Lo Mauro Antonella, Geri Elisabetta
UOC Recupero E Riabilitazione Funzionale, Ambito Territoriale Pisano, ASL Toscana Nordovest, Pisa, Italy.
ASST Fatebenefratelli Sacco, Milan, Italy.
J Pain Res. 2025 May 30;18:2751-2760. doi: 10.2147/JPR.S511708. eCollection 2025.
This real-world observational study was conducted to evaluate decrease in pain after 30-day administration of a new oral cetylated fatty acids (CFA) food supplement, assess if decreased pain resulted in a lower consumption of oral non-steroidal anti-inflammatory drugs (NSAIDs), and improvement in related gastric side effects. It was the first study of this food supplement in a real-world setting.
A hundred and twenty Italian primary care physicians recruited 562 patients who were prescribed oral CFA. Patients completed the Brief Pain Inventory (BPI) questionnaire at baseline and after 30 days of dosing. Their CFA intake adherence and use of NSAIDs were recorded. All analyses were done using R statistical software; p-value ≤ 0.005 was considered statistically significant.
We analyzed data of 196 males and 366 females aged in an average 49.2 years. After 30 days of CFA intake, we observed a statistically significant reduction (38.84%) in the overall pain score, 44.53% reduction in the interference score in daily activities, relief from pain within the previous 24 hours 47.16 (± 11.44%) at baseline and 62.14 (± 27.93%) after 30 days, and progressive reduction in NSAID intake frequency and total dose over time. More than half of participants (55.2%) reported improvement in gastric side effects typically associated with NSAID use.
Data analyses indicated that using the new oral CFA food supplement decreased pain, which helped improve the quality of life, better perform daily activities (interference reduced by 44.5%), and reduce painkiller consumption by 19.7% in terms of both dose and frequency. Half of participants (55.2%) rated NSAID-related hyperchlorhydria and heartburn as improved. Although placebo effect might have contributed, the results suggest that CFA may have a positive effect in patients with sub-acute and chronic musculoskeletal pain and can enhance therapies typically used in this population.
本真实世界观察性研究旨在评估新型口服乙酰化脂肪酸（CFA）食品补充剂服用30天后疼痛的减轻情况，评估疼痛减轻是否导致口服非甾体抗炎药（NSAIDs）的消费量降低，以及相关胃部副作用的改善情况。这是该食品补充剂在真实世界环境中的首次研究。
120名意大利初级保健医生招募了562名开具口服CFA处方的患者。患者在基线期和给药30天后完成简短疼痛问卷（BPI）。记录他们的CFA摄入量依从性和NSAIDs的使用情况。所有分析均使用R统计软件进行；p值≤0.005被认为具有统计学意义。
我们分析了196名男性和366名女性的数据，平均年龄为49.2岁。服用CFA 30天后，我们观察到总体疼痛评分有统计学意义的降低（38.84%），日常活动干扰评分降低44.53%，基线期前24小时内疼痛缓解率为47.16（±11.44%），30天后为62.14（±27.93%），且随着时间推移NSAIDs摄入频率和总剂量逐渐降低。超过一半的参与者（55.2%）报告与NSAIDs使用相关的胃部副作用有所改善。
数据分析表明，使用新型口服CFA食品补充剂可减轻疼痛，有助于改善生活质量，更好地进行日常活动（干扰减少44.5%），并在剂量和频率方面将止痛药消费量降低19.7%。一半的参与者（55.2%）将与NSAIDs相关的胃酸过多和胃灼热评为有所改善。尽管可能存在安慰剂效应，但结果表明CFA可能对亚急性和慢性肌肉骨骼疼痛患者有积极作用，并可增强该人群通常使用的治疗方法。
